Kiniksa Pharmaceuticals Stock Today
| KNSA Stock | USD 23.36 0.45 1.89% |
PerformanceOK
| Odds Of DistressBelow Average
|
Kiniksa Pharmaceuticals is trading at 23.36 as of the 22nd of March 2025, a 1.89 percent decrease since the beginning of the trading day. The stock's open price was 23.81. Kiniksa Pharmaceuticals has about a 40 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of May 2018 | Category Healthcare | Classification Health Care |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Kiniksa Pharmaceuticals, Ltd. The company has 42.01 M outstanding shares of which 2.96 M shares are now shorted by private and institutional investors with about 5.24 trading days to cover. More on Kiniksa Pharmaceuticals
Moving against Kiniksa Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Kiniksa Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsKiniksa Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kiniksa Pharmaceuticals' financial leverage. It provides some insight into what part of Kiniksa Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kiniksa Pharmaceuticals (KNSA) is traded on NASDAQ Exchange in USA. It is located in 23 Old Bond Street, London, United Kingdom, WIS 4PZ and employs 315 people. Kiniksa Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.73 B. Kiniksa Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 42.01 M outstanding shares of which 2.96 M shares are now shorted by private and institutional investors with about 5.24 trading days to cover.
Kiniksa Pharmaceuticals currently holds about 138.21 M in cash with 25.69 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.99.
Check Kiniksa Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationKiniksa Pharmaceuticals maintains a total of 42.01 Million outstanding shares. The majority of Kiniksa Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kiniksa Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kiniksa Pharmaceuticals. Please pay attention to any change in the institutional holdings of Kiniksa Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Kiniksa Ownership Details
Kiniksa Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 771.6 K | |
| Parkman Healthcare Partners Llc | 2024-12-31 | 765.5 K | |
| State Street Corp | 2024-12-31 | 729.6 K | |
| Fmr Inc | 2024-12-31 | 705.3 K | |
| Rice Hall James & Associates, Llc | 2024-12-31 | 642.8 K | |
| Tang Capital Management Llc | 2024-12-31 | 628.6 K | |
| Driehaus Capital Management Llc | 2024-12-31 | 613.5 K | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 521.9 K | |
| Geode Capital Management, Llc | 2024-12-31 | 492.6 K | |
| Blackrock Inc | 2024-12-31 | 3.6 M | |
| Braidwell Lp | 2024-12-31 | 3.5 M |
Kiniksa Pharmaceuticals Historical Income Statement
Kiniksa Stock Against Markets
Kiniksa Pharmaceuticals Corporate Management
| Madelyn Zeylikman | General SVP | Profile | |
| Melissa Manno | Senior Officer | Profile | |
| Ross Moat | Senior Officer | Profile | |
| Rachel Frank | Senior Communications | Profile | |
| Michael CPA | Chief Finance | Profile | |
| Chad Morin | Senior Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.59) | Revenue Per Share | Quarterly Revenue Growth 0.469 | Return On Assets |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.